Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVirios Therapeutics Llc

Virios Therapeutics Llc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-01-09T19:06:57.504634Z
Market Cap
5.81M

Momentum Score

…

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.16
Low
2.42
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.74
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.74
ROE
-95.14%
Net Debt
-3.32M
ROCE
-323.50%
Diluted EPS TTM
-0.27

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -12.25M -15.96M -10.35M -2.47M -2.11M
Net income -12.18M -15.96M -10.35M -2.77M -2.11M
Selling general administrative 4.25M 4.85M 9.81M 1.34M 1.11M
Ebit -12.32M -15.64M -10.35M -2.18M -1.96M
Ebitda -12.32M -15.64M -10.01M -2.18M -1.96M
Depreciation and amortization - - - - 0.00M
Operating income -12.32M -15.64M -10.01M -2.18M -1.96M
Other operating expenses 12.32M 15.64M 10.01M 2.18M 1.96M
Interest expense -0.07M 0.01M 0.38M 0.30M 0.15M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income 0.07M 0.01M -0.38M -0.30M -0.15M
Income tax expense -0.07M 0.32M -0.04M 0.30M 0.15M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 12.32M 15.64M 10.01M 2.18M 1.96M
Total other income expense net 0.07M -0.32M -0.34M -0.30M 0.00M
Net income from continuing ops -12.25M -15.96M -10.35M -2.47M -2.11M
Net income applicable to common shares -12.25M -15.96M -10.35M -2.47M -2.11M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.17M 8.37M 15.78M 31.47M 0.32M
Other current assets 0.85M 0.01M 0.00M 1.68M 0.01M
Total liab 0.36M 1.04M 1.28M 1.53M 5.26M
Total stockholder equity 3.81M 7.33M 14.50M 29.94M -4.94M
Other current liab 0.25M 0.47M 0.92M 1.16M 1.59M
Common stock 0.00M 0.00M 0.00M 0.00M 12.60M
Capital stock 0.00M 0.00M 0.00M 0.00M 12.68M
Retained earnings -61.47M -56.17M -43.93M -27.97M -17.62M
Cash 3.32M 7.03M 14.01M 29.80M 0.31M
Total current liabilities 0.36M 1.04M 1.28M 1.53M 1.62M
Net debt -3.32M -7.03M -14.01M -29.80M 3.33M
Short long term debt total - - - - 3.64M
Other stockholder equity 65.27M 63.50M 58.43M 57.91M 0.07M
Total current assets 4.17M 8.37M 15.78M 31.47M 0.32M
Net tangible assets - 7.33M 18.88M 29.94M -5.02M
Net receivables - - - 0.00M 0.00M
Long term debt - - - - 3.64M
Inventory - - - -0.00M -
Accounts payable 0.11M 0.57M 0.35M 0.37M 0.04M
Accumulated other comprehensive income 0.00M - - - -
Common stock total equity - - - 0.00M 12.60M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Change to liabilities 0.22M 0.27M 0.05M -0.09M 0.07M
Net borrowings - - 1.99M 2.43M 2.43M
Total cash from financing activities 4.49M -0.10M 33.38M 2.37M 1.15M
Change to operating activities -0.02M -0.32M -1.03M 0.41M 0.80M
Net income -12.25M -15.96M -10.35M -2.47M -2.11M
Change in cash -6.98M -15.79M 29.49M 0.28M -0.05M
Begin period cash flow 14.01M 29.80M 0.31M 0.03M 0.08M
End period cash flow 7.03M 14.01M 29.80M 0.31M 0.03M
Total cash from operating activities -11.47M -15.69M -3.90M -2.09M -1.20M
Issuance of capital stock 4.49M - 31.35M 0.00M 1.22M
Depreciation - - 0.05M - -
Dividends paid - 0.00M 0.00M - -
Sale purchase of stock - -0.30M - - -
Other cashflows from financing activities 4.49M 0.20M 2.03M 2.37M 1.15M
Change to netincome 0.58M 0.32M 7.37M 0.00M 0.02M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.20M -0.05M -0.97M 0.32M 0.87M
Stock based compensation 0.58M 0.32M 7.43M - -
Other non cash items - 16.01M -0.00M 0.07M 0.05M
Free cash flow -11.47M -15.69M -3.90M -2.09M -1.20M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Virios Therapeutics Llc

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

44 Milton Avenue, Alpharetta, GA, United States, 30009

866 620 8655

https://www.virios.com

4

Name Title Year Born
Mr. Gregory Duncan Chairman & CEO 1965
Mr. Ralph D. Grosswald M.P.H. Sr. VP of Operations 1969
Dr. R. Michael Gendreau M.D., Ph.D. Chief Medical Officer 1956
Ms. Angela Walsh CFO, SVP of Fin., Corp. Sec. & Treasurer 1967
Ms. Carol Duffy Ph.D. Chief Scientific Advisor NA
Dr. William L. Pridgen M.D. Founder & Director 1961
Ms. Angela Walsh CFO, SVP of Finance, Corporate Secretary & Treasurer 1967
Mr. Ralph D. Grosswald M.P.H. Senior Vice President of Operations 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…